Docket No. 3868-0111P

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application.

The claims have also been amended to remove the multiple dependencies in order to place the application into better form prior to examination.

Entry of the present amendment and favorable action on the above-identified application are earnestly solicited.

Attached hereto is a marked-up copy of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By _____
James M. Slattery, #28,380

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

JMS/ka
3868-0111P

Attachment: VERSION WITH MARKINGS TO SHOW CHANGES MADE

(Rev. 02/21/02)

Docket No. 3868-0111P

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

The claims have been amended as follows:

3. (Amended) Therapeutic system according to [one or more of Claims 1 to 2] Claim 1, characterized in that the vapour-deposited metal is aluminium.

4. (Amended) Therapeutic system according to [one or more of Claims 1 to 3] Claim 1, characterized in that the plastic films of the protective layer, which are provided with a vapour-deposited metal layer, are rendered [abhesive] adhesive on at least one side.

5. (Amended) Therapeutic system according to [one or more of Claims 1 to 4] Claim 1, characterized in that the plastic films are selected from the group of polyester, polyethylene, polypropylene, polyamide, polyurethane, polyvinyl chloride, polyvinylidene chloride, polyvinyl alcohol and ethylene-vinyl acetate copolymer.

6. (Amended) Therapeutic system according to [one or more of Claims 1 to 5] Claim 1, characterized in that the plastic films have a thickness between 0.004 to 1.0 mm, preferably between 0.010 and 0.5 mm.

7. (Amended) Therapeutic system according to [one or more of Claims 1 to 6] Claim 1, characterized in that it contains nitroglycerine as ingredient.

8. (Amended) Therapeutic system according to [one or more of Claims 1 to 6] Claim 1, characterized in that it contains nicotine as ingredient.

9. (Amended) Process for the manufacture of plastic films, provided with a vapour-deposited metal layer, for transdermal therapeutic systems according to [one or more of Claims 1 to 8] Claim 1, characterized in that to obtain absolutely impermeable double-face metal layers, the vapour deposition is performed under high vacuum in at least one operation.

10. (Amended) Process for the manufacture of plastic films, provided with a vapour-deposited metal layer, for transdermal therapeutic systems according to [one or more of Claims 1 to 8] Claim 1, characterized in that to obtain absolutely impermeable metal layers, the vapour deposition is performed with the aid of a plasma in at least one operation.

11. (Amended) Use of plastic films according to [Claims 1 to 10] Claim 1 for manufacturing dermal or transdermal therapeutic systems containing readily volatile active agents or auxiliary agents.